Targeting converging therapeutic pathways to overcome hypertension.
作者信息
Koh Kwang Kon, Quon Michael J
出版信息
Int J Cardiol. 2009 Mar 6;132(3):297-9. doi: 10.1016/j.ijcard.2008.11.150. Epub 2009 Jan 10.
Abstract
摘要
相似文献
1
Targeting converging therapeutic pathways to overcome hypertension.靶向汇聚治疗途径以克服高血压。
Int J Cardiol. 2009 Mar 6;132(3):297-9. doi: 10.1016/j.ijcard.2008.11.150. Epub 2009 Jan 10.
2
Hypercholesterolemia and Hypertension: Two Sides of the Same Coin.高胆固醇血症与高血压：同一枚硬币的两面。
Am J Cardiovasc Drugs. 2015 Dec;15(6):403-14. doi: 10.1007/s40256-015-0128-1.
3
Insulin Resistance and Endothelial Dysfunction Constitute a Common Therapeutic Target in Cardiometabolic Disorders.胰岛素抵抗与内皮功能障碍构成心脏代谢紊乱的共同治疗靶点。
Mediators Inflamm. 2016;2016:3634948. doi: 10.1155/2016/3634948. Epub 2016 Jun 20.
4
Diabetes and hypertension: a review.糖尿病与高血压：综述
Prim Care. 1991 Sep;18(3):509-24.
5
The Impact of Diabetes Mellitus on Cardiovascular Risk Onset in Children and Adolescents.糖尿病对儿童和青少年心血管风险发病的影响。
Int J Mol Sci. 2020 Jul 12;21(14):4928. doi: 10.3390/ijms21144928.
6
Endothelial function assessment in atherosclerosis: comparison of brachial artery flow‑mediated vasodilation and peripheral arterial tonometry.动脉粥样硬化中内皮功能评估：肱动脉血流介导的血管舒张与外周动脉张力测量法的比较
Pol Arch Med Wewn. 2013;123(9):443-52. doi: 10.20452/pamw.1879. Epub 2013 Sep 11.
7
[Insulin resistance, arterial hypertension and cardiovascular prevention. Therapeutic implications].[胰岛素抵抗、动脉高血压与心血管预防。治疗意义]
Presse Med. 1997 Apr 26;26(14):671-7.
8
Primary prevention of atherosclerotic cardiovascular disease: bringing clinicians and patients to the starting line.动脉粥样硬化性心血管疾病的一级预防：让临床医生和患者站在起跑线上。
J Am Coll Cardiol. 2014 Sep 9;64(10):969-70. doi: 10.1016/j.jacc.2014.06.1185.
9
Therapeutic interventions for hypertension in metabolic syndrome: a comprehensive approach.
Expert Rev Cardiovasc Ther. 2007 Mar;5(2):201-11. doi: 10.1586/14779072.5.2.201.
10
Arteries, myocardium, blood pressure and cardiovascular risk: towards a revised definition of hypertension.动脉、心肌、血压与心血管风险：迈向高血压的修订定义
J Hypertens. 1998 Dec;16(12 Pt 2):2117-24.
引用本文的文献
1
An analysis of the risk factors for premature coronary artery disease in young and middle-age Chinese patients with hypertension.中国中青年高血压患者冠状动脉疾病早发的危险因素分析。
Exp Clin Cardiol. 2013 Spring;18(2):89-92.
2
Differential metabolic actions of specific statins: clinical and therapeutic considerations.特定他汀类药物的差异化代谢作用：临床和治疗方面的考虑。
Antioxid Redox Signal. 2014 Mar 10;20(8):1286-99. doi: 10.1089/ars.2013.5531. Epub 2013 Sep 24.
3
Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction.联合治疗用于动脉粥样硬化的治疗或预防：重点关注脂质-肾素-血管紧张素系统的相互作用。
Atherosclerosis. 2010 Apr;209(2):307-13. doi: 10.1016/j.atherosclerosis.2009.09.007. Epub 2009 Sep 12.
4
The importance of considering alternative or combination strategies for lowering LDL-C.考虑采用替代策略或联合策略降低低密度脂蛋白胆固醇（LDL-C）的重要性。
Int J Cardiol. 2009 Aug 14;136(2):115-9. doi: 10.1016/j.ijcard.2009.03.035. Epub 2009 Apr 3.
本文引用的文献
1
Adiponectin and cardiovascular disease: response to therapeutic interventions.脂联素与心血管疾病：对治疗干预的反应
J Am Coll Cardiol. 2007 Feb 6;49(5):531-8. doi: 10.1016/j.jacc.2006.08.061. Epub 2007 Jan 19.
2
Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms.胰岛素抵抗与内皮功能障碍之间的相互关系：分子和病理生理机制。
Circulation. 2006 Apr 18;113(15):1888-904. doi: 10.1161/CIRCULATIONAHA.105.563213.
3
Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients.非诺贝特联合坎地沙坦治疗高甘油三酯血症高血压患者的附加有益作用。
Diabetes Care. 2006 Feb;29(2):195-201. doi: 10.2337/diacare.29.02.06.dc05-1418.
4
Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions.炎症标志物与代谢综合征：治疗干预的见解
J Am Coll Cardiol. 2005 Dec 6;46(11):1978-85. doi: 10.1016/j.jacc.2005.06.082. Epub 2005 Nov 9.
5
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.盎格鲁-斯堪的纳维亚心脏结局试验-降压分支（ASCOT-BPLA）：氨氯地平降压方案按需加用培哚普利与阿替洛尔按需加用苄氟噻嗪预防心血管事件的多中心随机对照试验
Lancet. 2005;366(9489):895-906. doi: 10.1016/S0140-6736(05)67185-1.
6
Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes.雷米普利与辛伐他汀联合治疗对2型糖尿病患者的血管及代谢影响
Hypertension. 2005 Jun;45(6):1088-93. doi: 10.1161/01.HYP.0000166722.91714.ba. Epub 2005 May 9.
7
Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients.氯沙坦联合辛伐他汀治疗高胆固醇血症合并高血压患者的附加有益作用。
Circulation. 2004 Dec 14;110(24):3687-92. doi: 10.1161/01.CIR.0000143085.86697.13. Epub 2004 Nov 29.
8
Hypercholesterolemia and hypertension have synergistic deleterious effects on coronary endothelial function.高胆固醇血症和高血压对冠状动脉内皮功能具有协同有害作用。
Arterioscler Thromb Vasc Biol. 2003 May 1;23(5):885-91. doi: 10.1161/01.ATV.0000069209.26507.BF. Epub 2003 Mar 27.
9
Risk stratification in hypertension: new insights from the Framingham Study.高血压的风险分层：弗明汉姆研究的新见解。
Am J Hypertens. 2000 Jan;13(1 Pt 2):3S-10S. doi: 10.1016/s0895-7061(99)00252-6.
10
Critical appraisal of recent studies on nifedipine and other calcium channel blockers in coronary artery disease and hypertension.硝苯地平及其他钙通道阻滞剂用于冠状动脉疾病和高血压的近期研究的批判性评价
Eur Heart J. 1996 Aug;17(8):1152-7. doi: 10.1093/oxfordjournals.eurheartj.a015031.
Zotero 插件